International Journal of

Clinical CardiologyISSN: 2378-2951


 Open Access DOI:10.23937/2378-2951/1410272

Effect of Edoxaban, F-Xa-Directed Oral Anticoagulant on Spontaneous Thrombolytic Activity in Apoe-/- and Ldlr-/- Double Knockout Mice

Kanae Hyodo, MS, Naotaka Ohta, PhD, Hiromitsu Ishii, MD and Tsutomu Yamashita, PhD*

Article Type: Original Article | First Published: December 01, 2022

The details of thrombolytic activity in occlusive disease associated with atherosclerotic lesions are not clear. This study investigated the novel effects of activated coagulation factor X (F-Xa)-directed oral anticoagulant (DOAC) edoxaban on in vivo thrombolytic activity and atherosclerosis progression. Mice were fed an experimental diet (edoxaban 15-50 mg/kg) for 18 weeks. The degree of progression of atherosclerosis was assessed as the area of atherosclerotic vessels as a percentage of the to...

 Open Access DOI:10.23937/2378-2951/1410271

siRNA-Induced Silencing of LP(a) Gene: An Ideal Choice to Prevent Genetic Risk of Myocardial Infarction

Muhammad Arslan

Article Type: Review Article | First Published: November 18, 2022

Elevated level of lipoprotein (a) gene is the main cause of inherited risk of myocardial infarction (MI). Several RNA based therapies are being developed to reduce the expression of LP(a) gene, but none of them are neither available in market, nor have been declared as perfect choice for treatment. An American multinational biopharmaceutical company, Amgen Inc, has recently disclosed remarkable test results of phase II trial of Olpasiran [a small interfering RNA-based (siRNA) therapy to target L...

Volume 9
Issue 6